一种多品种定期订货策略

针对多品种分组联合订货策略的制定,提出了求解订货策略的一种启发式方法,简化了最优解的求解过程,丰富了订货模型及其求解方法。     

西部大开发中云南的角色定位

在西部大开发中,云南要结合绿色资源优势、人文资源优势、区位优势,准确地把握自身在西部大开发中的角色、地位,进行高层次、高起点的战略规划,以新思路来发展云南区域特色经济,探索出最能发挥云南优势的经济发展模式,大力发展绿色产业、旅游业、出口工业,实现云南经济的跨越式发展,使云南在西部大开发中有所作为。     

用层次分析模型选择我国铁路营业站

当前我国铁路既有线仍存在营业站设置过多,布局分散的问题,对铁路运输产生了诸多不利的影响。因此,如何选择合理的营业站,对铁路当前生产力布局调整具有重要的现实意义。     

如何充分利用第三方物流服务

本文对托运人如何充分利用第三方物流服务,进行了详细地分析,并引经据典,提出了很我可操作性的建议,具有一定的实用价值。     

加息对我国房地产市场的效应分析

本文从我国房地产市场中存在的问题入手,着重分析央行加息对我国房地产市场可能产生的效应,认为加息将有利于消除房地产泡沫,缓解房地产市场供求矛盾,并在此基础上提出确保央行加息效应的政策建议。     

Partnership or self-reliance entry modes: Large and small technology-based enterprises’ strategies in overseas markets

This study compares large firms against small and medium-sized firms in technology industries and assesses the differences between them in the choices between partnership and self-reliance entry modes. A sample of 166 large, small, and medium-sized firms in technology industries was analyzed using LISREL 8.30. Results indicate that, given innovative advantage, large and small and medium-sized firms both prefer self-reliance entry modes. With violent market dynamism, large firms prefer self-reliance entry modes while small and medium-sized firms prefer partnership entry modes. When high promotional effort is required, small and medium-sized firms prefer partnership entry modes and large firms may prefer partnership entry modes as well. This study provides important guidance for managers of large and small technology-based firms to select their entry modes when they enter overseas markets.     

中国传统文化价值观下的团队建设

文章通过比较分析中、日文化差异对团队建设的不同影响,找出了影响中国团队建设的文化因素,并在此基础上构建了一个包含五个关键成功因素的团队框架以供进一步探讨。     

道路桥梁施工中混凝土裂缝成因及应对措施分析

道路桥梁工程作为我国社会经济建设中的重要组成部分,有着十分关键的现实意义.在城市化进程下,基于城市的交通需求和区域交通需求,也给道路桥梁工程的建设带来了更多的机遇和挑战.混凝土的裂缝问题长久以来都在影响着道路桥梁工程的质量和安全.基于此,还需要设计施工过程中进一步关注裂缝问题,持续优化裂缝问题,完善工程整体属性.因此,本文立足问题,提出几点建议,以备后续参考.     

EXCEL会计核算中记账凭证的查询与打印设计

在电算化会计核算中,记账凭证查询与打印是不可缺少的一个环节。本文通过建立凭证框架,设置查询公式,引入VBA代码操作来实现会计记账凭证的查询以及批量打印工作。     

Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk,secondary-prevention population in the US payer context

Aim: To estimate real-world cardiovascular disease (CVD) burden and value-based price range of evolocumab for a US-context, high-risk, secondary-prevention population.

Materials and methods: Burden of CVD was assessed using the UK-based Clinical Practice Research Datalink (CPRD) in order to capture complete CV burden including CV mortality. Patients on standard of care (SOC; high-intensity statins) in CPRD were selected based on eligibility criteria of FOURIER, a phase 3 CV outcomes trial of evolocumab, and categorized into four cohorts: high-risk prevalent atherosclerotic CVD (ASCVD) cohort (n?=?1448), acute coronary syndrome (ACS) (n?=?602), ischemic stroke (IS) (n?=?151), and heart failure (HF) (n?=?291) incident cohorts. The value-based price range for evolocumab was assessed using a previously published economic model. The model incorporated CPRD CV event rates and considered CV event reduction rate ratios per 1?mmol/L reduction in low-density lipoprotein-cholesterol (LDL-C) from a meta-analysis of statin trials by the Cholesterol Treatment Trialists Collaboration (CTTC), i.e. CTTC relationship.

Results: Multiple-event rates of composite CV events (ACS, IS, or coronary revascularization) per 100 patient-years were 12.3 for the high-risk prevalent ASCVD cohort, and 25.7, 13.3, and 23.3, respectively, for incident ACS, IS, and HF cohorts. Approximately one-half (42%) of the high-risk ASCVD patients with a new CV event during follow-up had a subsequent CV event. Combining these real-world event rates and the CTTC relationship in the economic model, the value-based price range (credible interval) under a willingness-to-pay threshold of $150,000/quality-adjusted life-year gained for evolocumab was $11,990 ($9,341–$14,833) to $16,856 ($12,903–$20,678) in ASCVD patients with baseline LDL-C levels ≥70?mg/dL and ≥100?mg/dL, respectively.

Conclusion: Real-world CVD burden is substantial. Using the observed CVD burden in CPRD and the CTTC relationship, the cost-effectiveness analysis showed that, accounting for uncertainties, the expected value-based price for evolocumab is higher than its current annual cost, as long as the payer discount off list price is greater than 20%.